Genmab — Maj 2019
-
enig bibob 16.56. Produkter, know-how og medarbejderstaben er intakt, at så ham der uddelegerer arbejdet til andre forsvinder, kan på ingen måde berettige et kursfald af den størrelsesorden vi har set i dag. Lidt det samme skete i Demant, da den overvurderede Lars Kolind smed tøjlerne.
-
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced today that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys's investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. "The initiation of our first phase 3 trial represents another important milestone in advancing MOR202/TJ202 towards registration with the hope of providing more therapeutic options for multiple myeloma patients globally. Under I-Mab's fast-to-market development strategy, the phase 3 study, if successful, could lead to a biologics license application (BLA) in Greater China.
Yahoo Finance (finance.yahoo.com)
-
Det ser ud til at Ambu har fået god mand med en solid baggrund fra bla. J&J.
-
Den hedder P/E 70 efter dagens fald.
-
-
Jeg så lige et norsk nyhedsbureau være ude med, at Goldman Sachs har nærlæst de nye amr toldlove og bemærket, at skibe der har forladt kinesisk havn inden 10. maj ikke vil blive belagt med den høje told. Det skulle iflg GS give et vindue på et par uger, hvor fortoldning ikke vil finde sted i praksis.
-
Goldman Sachs noterer at detaljer i USAs melding om tarifføkning indikerer at eksport som allerede har forlatt kinesiske havner før 10. mai ikke vil bli rammet av økningen. Dette danner et uoffisielt vindu i muligens et par uker hvor forhandlingene kan fortsette, mener investeringsbanken, ifølge CNBC.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind